287 related articles for article (PubMed ID: 24994482)
1. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.
Sahin S; Yuce M; Alacam H; Karabekiroglu K; Say GN; Salıs O
Int J Psychiatry Clin Pract; 2014 Oct; 18(4):280-7. PubMed ID: 24994482
[TBL] [Abstract][Full Text] [Related]
2. Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder.
Gurbuz F; Gurbuz BB; Celik GG; Yildirim V; Ucakturk SA; Seydaoglu G; Ucakturk EM; Topaloglu AK; Yuksel B
J Pediatr Endocrinol Metab; 2016 Jan; 29(1):85-92. PubMed ID: 26352086
[TBL] [Abstract][Full Text] [Related]
3. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD).
Amiri A; Torabi Parizi G; Kousha M; Saadat F; Modabbernia MJ; Najafi K; Atrkar Roushan Z
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():20-4. PubMed ID: 23933054
[TBL] [Abstract][Full Text] [Related]
4. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
Işeri E; Kiliç BG; Senol S; Karabacak NI
Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
[TBL] [Abstract][Full Text] [Related]
5. Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study.
Akay AP; Resmi H; Güney SA; Erkuran HÖ; Özyurt G; Sargin E; Topuzoglu A; Tufan AE
Eur Child Adolesc Psychiatry; 2018 Jan; 27(1):127-135. PubMed ID: 28710695
[TBL] [Abstract][Full Text] [Related]
6. BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.
Cubero-Millán I; Ruiz-Ramos MJ; Molina-Carballo A; Martínez-Serrano S; Fernández-López L; Machado-Casas I; Tortosa-Pinto P; Ruiz-López A; Luna-Del-Castillo JD; Uberos J; Muñoz-Hoyos A
Psychopharmacology (Berl); 2017 Jan; 234(2):267-279. PubMed ID: 27807606
[TBL] [Abstract][Full Text] [Related]
7. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
8. Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats.
Kim H; Heo HI; Kim DH; Ko IG; Lee SS; Kim SE; Kim BK; Kim TW; Ji ES; Kim JD; Shin MS; Choi YW; Kim CJ
Neurosci Lett; 2011 Oct; 504(1):35-9. PubMed ID: 21907264
[TBL] [Abstract][Full Text] [Related]
9. Brain-derived neurotrophic factor (BDNF) levels in children and adolescents before and after stimulant use a systematic review and metanalysis.
de Lucca MS; Pimentel MEO; Raimundo CKO; Henriques BD; Moreira TR; Cardoso SA; de Miranda DM
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jul; 125():110761. PubMed ID: 37044279
[TBL] [Abstract][Full Text] [Related]
10. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
13. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
14. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
Lakić A
Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
[TBL] [Abstract][Full Text] [Related]
17. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
[TBL] [Abstract][Full Text] [Related]
18. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
[No Abstract] [Full Text] [Related]
19. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
20. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
Fumagalli F; Cattaneo A; Caffino L; Ibba M; Racagni G; Carboni E; Gennarelli M; Riva MA
Pharmacol Res; 2010 Dec; 62(6):523-9. PubMed ID: 20691787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
